Display options
Cite
Lhommée E, Batir A, Quesada JL, et al. Dopamine and the biology of creativity: lessons from Parkinson's disease. Front Neurol. 2014;5:55doi: 10.3389/fneur.2014.00055.
Lhommée, E., Batir, A., Quesada, J. L., Ardouin, C., Fraix, V., Seigneuret, E., Chabardès, S., Benabid, A. L., Pollak, P., & Krack, P. (2014). Dopamine and the biology of creativity: lessons from Parkinson's disease. Frontiers in neurology, 555. https://doi.org/10.3389/fneur.2014.00055
Lhommée, Eugénie, et al. "Dopamine and the biology of creativity: lessons from Parkinson's disease." Frontiers in neurology vol. 5 (2014): 55. doi: https://doi.org/10.3389/fneur.2014.00055
Lhommée E, Batir A, Quesada JL, Ardouin C, Fraix V, Seigneuret E, Chabardès S, Benabid AL, Pollak P, Krack P. Dopamine and the biology of creativity: lessons from Parkinson's disease. Front Neurol. 2014 Apr 22;5:55. doi: 10.3389/fneur.2014.00055. eCollection 2014. PMID: 24795692; PMCID: PMC4001035.
Copy Download .nbib Format: NLM
Share it on

Front Neurol. 2014 Apr 22;5:55. doi: 10.3389/fneur.2014.00055. eCollection 2014.

Dopamine and the biology of creativity: lessons from Parkinson's disease.

Frontiers in neurology

Eugénie Lhommée, Alina Batir, Jean-Louis Quesada, Claire Ardouin, Valérie Fraix, Eric Seigneuret, Stéphan Chabardès, Alim-Louis Benabid, Pierre Pollak, Paul Krack

Affiliations

  1. U836, INSERM , Grenoble , France ; University of Grenoble Alpes, GIN , Grenoble , France ; Movement Disorder Unit, CHU de Grenoble , Grenoble , France.
  2. Centre d'Investigation Clinique, CHU de Grenoble, Université Joseph Fourier , Grenoble , France.
  3. U836, INSERM , Grenoble , France ; University of Grenoble Alpes, GIN , Grenoble , France ; Department of Neurosurgery, CHU de Grenoble , Grenoble , France.
  4. Department of Neurosurgery, CHU de Grenoble , Grenoble , France.

PMID: 24795692 PMCID: PMC4001035 DOI: 10.3389/fneur.2014.00055

Abstract

BACKGROUND: Parkinson's disease (PD) is characterized by reduced flexibility, conceptualization, and visuo-spatial abilities. Although these are essential to creativity, case studies show emergence of creativity during PD. Knowledge about the role of dopamine in creativity so far only stems from a few case reports. We aim at demonstrating that creativity can be induced by dopaminergic treatments in PD, and tends to disappear after withdrawal of dopamine agonists.

METHODS: Eleven consecutive creative PD patients were selected from candidates for subthalamic nucleus deep brain stimulation (STN DBS) surgery, and compared to 22 non-creative control PD patients. Motor disability (UPDRS III), cognition (Frontal score, Mattis scale), and behavior (Ardouin scale) were assessed before surgery and 1 year after.

RESULTS: Before surgery, whereas cognitive and motor assessments were similar between groups, dopamine agonist (but not levodopa) dosages were higher in creative patients (p = 0.01). The Ardouin scale revealed also a specific psycho-behavioral profile of creative patients which had higher scores for mania (p < 0.001), hobbyism (p = 0.001), nocturnal hyperactivity (p = 0.041), appetitive functioning (p = 0.003), and ON euphoria (p = 0.007) and lower scores for apathy and OFF dysphoria (p = 0.04 for each). Post-operative motor, cognitive, and behavioral scores as dopaminergic treatment dosages were equivalent between groups. Motor improvement allowed for a 68.6% decrease in dopaminergic treatment. Only 1 of the 11 patients remained creative after surgery. Reduction of dopamine agonist was significantly correlated to the decrease in creativity in the whole population of study (Spearman correlation coefficient ρ = 0.47 with confidence index of 95% = 0.16; 0.70, p = 0.0053).

CONCLUSION: Creativity in PD is linked to dopamine agonist therapy, and tends to disappear after STN DBS in parallel to reduction of dopamine agonists, which are relatively selective for the mesolimbic D3 dopamine receptors.

Keywords: Parkinson’s disease; STN DBS; creativity; dopamine; impulse control disorders

References

  1. J Neurol Sci. 2009 Jan 15;276(1-2):138-42 - PubMed
  2. Acta Physiol Scand Suppl. 1971;367:95-122 - PubMed
  3. Mov Disord. 2006 Feb;21(2):285-6 - PubMed
  4. Behav Neurosci. 2013 Apr;127(2):256-61 - PubMed
  5. Neurology. 2001 Jun;56(11 Suppl 5):S1-S88 - PubMed
  6. Brain. 2010 Apr;133(Pt 4):1111-27 - PubMed
  7. J Neurol. 2006 Jul;253(7):955-6 - PubMed
  8. CNS Spectr. 2008 Aug;13(8):690-8 - PubMed
  9. Mov Disord. 2010 Mar 15;25(4):493-6 - PubMed
  10. Can J Psychiatry. 2011 Mar;56(3):132-43 - PubMed
  11. Cortex. 1976 Dec;12(4):313-24 - PubMed
  12. Ann Neurol. 1996 May;39(5):561-73 - PubMed
  13. Psychiatry. 1989 May;52(2):125-34 - PubMed
  14. Ann N Y Acad Sci. 2003 Nov;1003:241-9 - PubMed
  15. Cognition. 2010 Jun;115(3):458-65 - PubMed
  16. J Comp Neurol. 2005 Dec 5;493(1):147-53 - PubMed
  17. Neurology. 1986 Sep;36(9):1179-85 - PubMed
  18. PLoS One. 2010 May 17;5(5):e10670 - PubMed
  19. J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):134-9 - PubMed
  20. Neurology. 2012 Mar 27;78(13):998-1006 - PubMed
  21. J Clin Psychol. 1984 Nov;40(6):1365-7 - PubMed
  22. J Neurol. 1997 Jan;244(1):2-8 - PubMed
  23. Adv Neurol. 1999;80:471-9 - PubMed
  24. Behav Neurol. 2006;17(2):105-8 - PubMed
  25. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8 - PubMed
  26. Neurobiol Aging. 2003 Mar-Apr;24(2):197-211 - PubMed
  27. Neuropsychopharmacology. 2010 Jan;35(1):217-38 - PubMed
  28. Br J Psychiatry. 2011 Nov;199(5):351-2 - PubMed
  29. J Neurol Sci. 2009 Jan 15;276(1-2):179-83 - PubMed
  30. Mov Disord. 2006 Jun;21 Suppl 14:S290-304 - PubMed
  31. Mov Disord. 2013 Mar;28(3):404-5 - PubMed
  32. Mov Disord. 2011 Mar;26(4):578-86 - PubMed
  33. Brain. 2000 Apr;123 ( Pt 4):733-45 - PubMed
  34. Neuropsychopharmacology. 2001 Feb;24(2):97-129 - PubMed
  35. J Clin Neurosci. 2009 Sep;16(9):1148-52 - PubMed
  36. Rev Neurol (Paris). 2009 Nov;165(11):845-56 - PubMed
  37. Brain. 2012 May;135(Pt 5):1463-77 - PubMed
  38. Acta Neurol Belg. 1990;90(4):207-17 - PubMed
  39. Mov Disord. 2001 Nov;16(6):1175-6 - PubMed
  40. Eur J Neurol. 2012 Mar;19(3):468-72 - PubMed
  41. Mov Disord. 2009 Jun 15;24(8):1211-6 - PubMed
  42. J Neurol. 2009 May;256(5):816-9 - PubMed
  43. Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17113-8 - PubMed
  44. Mov Disord. 2007 Jan;22(1):99-104 - PubMed
  45. N Engl J Med. 2003 Nov 13;349(20):1925-34 - PubMed
  46. Arch Neurol. 2010 May;67(5):589-95 - PubMed

Publication Types